MUM1/IRF4: A review

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 4, 2010, Pages 301-310

  Gualco, Gabriela ^a   Weiss, Lawrence M ^b   Bacchi, Carlos E ^a  

^a Consultoria em Patologia ^*  (Brazil)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

immunohistochemistry; LSIRF; lymphocyte specific interferon regulatory factor; lymphoma; multiple myeloma oncogene 1; MUM1 IRF4

Indexed keywords

CD30 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; I KAPPA B; ICSTAT ANTIBODY; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 4; LATENT MEMBRANE PROTEIN 1; MESSENGER RNA; MONOCLONAL ANTIBODY; MUM 1P ANTIBODY; OCTAMER TRANSCRIPTION FACTOR 2; POLYCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN BCL 6; SYNDECAN 1; SYNTAXIN 1; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG;

APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER SURVIVAL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; EPSTEIN BARR VIRUS INFECTION; FOLLICULAR LYMPHOMA; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GERMINAL CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; T LYMPHOCYTE; UPREGULATION;

HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; LYMPHOMA, B-CELL; MULTIPLE MYELOMA; ONCOGENES; TUMOR MARKERS, BIOLOGICAL;

EID: 77954114222     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181cf1126     Document Type: Review

References (77)

1. Yamagata T, Nishida J, Tanaka S, et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol. 1996;16:1283-1294.
2. Gupta S, Jiang M, Anthony A, et al. Lineage-specific modulation of interleukin 4 signaling by interferon regulatory factor 4. J Exp Med. 1999;190:1837-1848.
3. Tanaka N, Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol. 2000;10:73-81.
4. Yoshida S, Nakazawa N, Iida S, et al. Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia. 1999;13:1812-1816.
5. Taniguchi T, Ogasawara K, Takaoka A, et al. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;19:623-655.
6. Harada H, Taniguchi T, Tanaka N. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie. 1998;80:641-650.
7. Ponzoni M, Arrigoni G, Doglioni C. New transcription factors in diagnostic hematopathology. Adv Anat Pathol. 2007;14:25-35.
8. Fanzo JC, Hu CM, Jang SY, et al. Regulation of lymphocyte apoptosis by interferon regulatory factor 4 (IRF-4). J Exp Med. 2003;197:303-314.
9. Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 1997;8:293-312.
10. Pernis AB. The role of IRF-4 in B and T cell activation and differentiation. J Interferon Cytokine Res. 2002;22:111-120.
11. Ozato K, Tailor P, Kubota T. The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem. 2007;282: 20065-20069.
12. Lu R. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol. 2008;29:487-492.
13. Kanno Y, Levi BZ, Tamura T, et al. Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU.1 complex. J Interferon Cytokine Res. 2005;25:770-779.
14. Tamura T, Yanai H, Savitsky D, et al. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535-584.
15. Grossman A, Mittrucker HW, Nicholl J, et al. Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25. Genomics. 1996;37: 229-233.
16. Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997; 17:226-230.
17. Shaffer AL, Emre NC, Lamy L, et al. LM. IRF4 addiction in multiple myeloma. Nature. 2008;454:226-231.
18. Tsuboi K, Iida S, Inagaki H, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia. 2000;14:449-456.
19. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95:2084-2092.
20. Shaffer AL, Emre NC, Romesser PB, et al. IRF4: immunity. Malignancy! Therapy? Clin Cancer Res. 2009;15:2954-2961.
21. Mittrucker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275:540-543.
22. Matsuyama T, Grossman A, Mittrucker HW, et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element ISRE. Nucleic Acids Res. 1995;23:2127-2136.
23. Grumont RJ, Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of inter-feron-regulated gene expression by rel/nuclear factor kappaB. J Exp Med. 2000;191:1281-1292.
24. Shaffer AL, Wright G, Yang L, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev. 2006;210:67-85.
25. Shaffer AL, Rosenwald A, Hurt EM, et al. Signatures of the immune response. Immunity. 2001;15:375-385.
26. Nelson N, Kanno Y, Hong C, et al. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J Immunol. 1996;156:3711-3720.
27. Brass AL, Kehrli E, Eisenbeis CF, et al. Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibi-tion and ternary complex formation with the Ets factor PU.1. Genes Dev. 1996;10:2335-2347.
28. Marecki S, Atchison ML, Fenton MJ. Differential expression and distinct functions of IFN regulatory factor 4 and IFN consensus sequence binding protein in macrophages. J Immunol. 1999;163: 2713-2722.
29. Martinez A, Pittaluga S, Rudelius M, et al. Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker. Am J Surg Pathol. 2008;32:1190-1200.
30. Yamada M, Asanuma K, Kobayashi D, et al. Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes. Anticancer Res. 2001;21:633-638.
31. Haarer CF, Roberts RA, Frutiger YM, et al. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med. 2006;130:1819-1824.
32. Hu CM, Jang SY, Fanzo JC, et al. Modulation of T cell cytokine production by interferon regulatory factor-4. J Biol Chem. 2002; 277:49238-49246.
33. Sciammas R, Shaffer AL, Schatz JH, et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25:225-236.
34. Rengarajan J, Mowen KA, McBride KD, et al. Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med. 2002;195:1003-1012.
35. Lohoff M, Mittrucker H W, Brustle A, et al. Enhanced TCR-induced apoptosis in interferon regulatory factor 4-deficient CD4(+) Th cells. J Exp Med. 2004;200:247-253.
36. Tamura T, Tailor P, Yamaoka K, et al. IFN regulatory factor-4 and-8 govern dendritic cell subset development and their functional diversity. J Immunol. 2005;174:2573-2581.
37. Heintel D, Zojer N, Schreder M, et al. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia. 2008;22:441-445.
38. Natkunam Y, Warnke RA, Montgomery K, et al. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol. 2001;14:686-694.
39. Gaidano G, Carbone A. MUM1: a step ahead toward the understanding of lymphoma histogenesis. Leukemia. 2000;14:563-566.
40. Craig F, Soma L, Melan M, et al. MUM1/IRF4 expression in the circulating compartment of chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49:273-280.
41. Naresh KN. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica. 2007;92:267-268.
42. Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol. 2005;18:1113-1120.
43. Tun HW, Personett D, Baskerville KA, et al. Pathway analysis of primary central nervous system lymphoma. Blood. 2008;111:3200-3210.
44. Coupland SE, Loddenkemper C, Smith JR, et al. Expression of immunoglobulin transcription factors in primary intraocular lym-phoma and primary central nervous system lymphoma. Invest Ophthalmol Vis Sci. 2005;46:3957-3964. (Pubitemid 44264593)
45. Chuang SS, Ye H, Du MQ, et al. Histopathology and immuno-histochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Pathol. 2007;128:558-564.
46. Valsami S, Pappa V, Rontogianni D, et al. A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. Haematologica. 2007;92:1343-1350.
47. Carbone A, Gloghini A, Aldinucci D, et al. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol. 2002;117:366-372.
48. Benner MF, Jansen PM, Meijer CJ, et al. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol. 2009;161:121-127.
49. Kempf W, Kutzner H, Cozzio A, et al. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol. 2008;158: 1280-1287.
50. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23:574-580.
51. Imaizumi Y, Kohno T, Yamada Y, et al. Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia. Jpn J Cancer Res. 2001;92:1284-1292.
52. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histo-genetic subsets of human immunodeficiency virus-related lympho-mas. Blood. 2001;97:744-751.
53. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103: 275-282.
54. Gualco G, Queiroga EM, Weiss LM, et al. Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma. Hum Pathol. 2009;40:565-571.
55. Gualco G, Weiss L, Harrington W, et al. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. Am J Surg Pathol. 2009;33:1815-1822.
56. Gualco G, Weiss L, Harrington W, et al. BCL6, MUM1, and CD10 expression in mantle cell lymphoma. Appl Immunohistochem Mol Morphol. 2009. [Epub ahead of print] PubMed PMID: 19826251.
57. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
58. Chang CC, McClintock S, Cleveland RP, et al. Immunohisto-chemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28:464-470.
59. van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:4135-4142.
60. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, et al. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol. 2009;22:1094-1101.
61. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208:714-723.
62. Sundram U, Kim Y, Mraz-Gernhard S, et al. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol. 2005;32: 227-234.
63. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162:243-253.
64. Pileri SA, Zinzani PL, Gaidano G, et al; International Extranodal Lymphoma Study Group. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S21-S26
65. Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
66. Gormley RP, Madan R, Dulau AE, et al. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases. Am J Clin Pathol. 2005;124:790-798.
67. Carbone A, Gloghini A, Cozzi MR, et al. Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis. Br J Haematol. 2000;111:247-257.
68. Chang CC, Lorek J, Sabath DE, et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood. 2002;100:4671-4675. (Pubitemid 35429714)
69. Ito M, Iida S, Inagaki H, et al. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res. 2002;93:685-694.
70. Sharma S, Grandvaux N, Mamane Y, et al. Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. J Immunol. 2002;169:3120-3130.
71. Mamane Y, Sharma S, Grandvaux N, et al. IRF-4 activities in HTLV-I-induced T cell leukemogenesis. J Interferon Cytokine Res. 2002;22:135-143.
72. Schmidt M, Hochhaus A, Konig-Merediz SA, et al. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. J Clin Oncol. 2000;18:3331-3338.
73. Gauzzi MC, Purificato C, Conti L, et al. IRF-4 expression in the human myeloid lineage: up-regulation during dendritic cell differentiation and inhibition by 1alpha,25-dihydroxyvitamin D3. J Leukoc Biol. 2005;77:944-947.
74. Lehtonen A, Veckman V, Nikula T, et al. Differential expression of IFN regulatory factor 4 gene in human monocyte-derived dendritic cells and macrophages. J Immunol. 2005;175:6570-6579.
75. Xu D, Zhao L, Del Valle L, et al. Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J Virol. 2008;82:6251-6258.
76. Queiroga EM, Gualco G, Chioato L, et al. Viral studies in Burkitt lymphoma: association with Epstein-Barr virus but not HHV-8. Am J Clin Pathol. 2008;130:186-192.
77. Sundram U, Harvell JD, Rouse RV, et al. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and Melan A. Mod Pathol. 2003;16: 802-810.